Aardvark Therapeutics (AARD) Accumulated Expenses (2024 - 2026)
Aardvark Therapeutics (AARD) posted Accumulated Expenses of $6.8 million for Q1 2026, down 15.68% sequentially from $8.0 million in Q4 2025, and up 123.6% YoY from $3.0 million in Q1 2025.
Aardvark Therapeutics (AARD) Accumulated Expenses (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Accumulated Expenses for 3 years, with the latest figure at $6.8 million in Q1 2026.
- Quarterly Accumulated Expenses rose 123.6% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (up 123.6% YoY) and the FY2025 annual result came in at $8.0 million, up 3471.11% from the prior year.
- Accumulated Expenses fell to $6.8 million in Q1 2026 per AARD's latest filing, from $8.0 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $8.0 million in Q4 2025 and troughed at $225000.0 in Q4 2024.
- A 3-year average of $4.2 million and a median of $3.9 million in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2025 and 2026: Accumulated Expenses surged 3471.11% in 2025, then jumped 123.6% in 2026.
- Over 3 years, Accumulated Expenses stood at $225000.0 in 2024, then soared by 3471.11% to $8.0 million in 2025, then declined by 15.68% to $6.8 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $6.8 million, $8.0 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.90 Mn |
| Mar 31, 2026 | 6.78 Mn |
| Dec 31, 2025 | 8.04 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Jun 30, 2025 | 4.84 Mn |
| Mar 31, 2025 | 3.03 Mn |
| Dec 31, 2024 | 225,000.00 |